Livzon Pharmaceutical Group Inc(000513) 2 announced on February 25 that the company received the notice of approval for clinical trial of drugs issued by the State Drug Administration on February 22 and agreed to carry out clinical trial of lz001 tablets.
Lz001 tablet is a new generation of anti drug resistant ros1 / ntrk / ALK multi-target inhibitor developed by the company in cooperation with Zhejiang cognate Kang Pharmaceutical Co., Ltd. It is mainly used to treat solid tumors with ros1 / ntrk / ALK multi-target mutation dominated by non-small cell lung cancer.
As of the disclosure date of the announcement, the accumulated direct investment in R & D expenses of lz00 was 32.226 million yuan.
According to the food and Drug Administration and relevant databases, as of the disclosure date of the announcement, lz001 similar multi-target chemicals with drug resistance have not been listed in China, one is in the stage of import registration and application, and two have been approved for clinical trials (including companies). (Huang Shu)
